Genmab — Juni 2017
-
N
ew in ClinicalTrials: A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis - NCT03201965 - https://clinicaltrials.gov/ct2/show/NCT03201965?term=daratumumab+OR+ofatumumab&lup_s=06%2F27%2F2017&rank=1 -
der er mange gode forklaringer på faldet i dag. stor warrantudnyttelse i går, stort us fald i går - og måske ikke mindst stort fald i USDEUR (og forventet fortsat fald fra IMF)
-
Det er lige før, at det er uforståeligt, at aktien ikke er faldet mere...
-
H3? er det oldboysfodbold?
-
vent til US recepttallene for august, så skal i se løjer
-
hehe - tak for clarification
Der må næsten komme en meddelelse om insidersalg -
david fik 45k aktier, jan fik 90k aktier og andre medarbejdere fik lidt over 23k aktier
-
næh - de andre fik +28k atier
-
Danskes bruttosalg kom op på k 151,5 aktier - så tallene minder lidt om hinanden
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind